{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Pharmacologic Substance[C1909]|Biological Agent[C307]|Antigen[C268]" in comments (approximate match)
Status:
Possibly Marketed Outside US
Source:
NCT03855176: Phase 4 Interventional Completed Hepatitis A
(2017)
Source URL:
First approved in 1996
Source:
BLA103606
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT02121145: Phase 4 Interventional Unknown status Healthy
(2013)
Source URL:
First approved in 1992
Source:
BLA103123
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA103931
(1980)
Source URL:
First approved in 1980
Source:
BLA103931
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Canada:BACILLUS CALMETTE-GUERIN (BCG) SUBSTRAIN CONNAUGHT
Source URL:
Class:
STRUCTURALLY DIVERSE
Class:
STRUCTURALLY DIVERSE
Class:
STRUCTURALLY DIVERSE
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(1989)
First approved in 1989
Class:
CONCEPT
Status:
Possibly Marketed Outside US
First approved in 2002
Source:
BLA103666
Source URL:
Class:
CONCEPT